This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J.P. Morgan Healthcare Confab Live Blog: Day Three

 

SAN FRANCISCO (TheStreet) -- Here we are, the final live blog of the J.P. Morgan Healthcare Conference 2014. It's Wednesday, hump day, featuring presentations from MannKind (MNKD), Keryx Pharma  (KERX - Get Report), Alexion Pharma (ALXN - Get Report), Geron (GERN - Get Report) and Sarepta Therapeutics (SRPT).

By now, you know the drill. I will be posting news updates and analysis throughout the day, live from the presentation rooms and breakout (Q&A) sessions. You can also follow me on Twitter, my handle is @adamfeuerstein. Your best bet is to check back into the live blog several times throughout the day. Feel free to ping me with questions and comments. I'll do my best to respond and keep the live blog as interactive as possible.

Here's my schedule for the day, preliminary, subject to change. All times Eastern.

MannKind 10:30 am
Keryx 11:30 am
Alexion 12:30 pm
Newlink Genetics (NLNK) 1 pm
Bluebird Bio  (BLUE) 1:30 pm
Geron 4:30 pm
Exelixis (EXEL) 5 pm
Morphosys 7 pm
Sarepta Therapeutics 7:30 pm

Sleep: 8 pm until well into tomorrow.


-- Reported by Adam Feuerstein in San Francisco.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ALXN $175.61 -2.50%
GERN $4.08 -5.00%
KERX $11.01 -3.50%
MNKD $4.62 -3.70%
AAPL $132.58 1.80%

Markets

DOW 18,051.88 -28.26 -0.16%
S&P 500 2,114.39 -3.30 -0.16%
NASDAQ 5,073.7190 -18.3660 -0.36%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs